Joshua Zeidner
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (NCT05442216) | Joshua Zeidner | 2024-05-01 |
Track Joshua Zeidner automatically
Every clearance here is in the API, with alerts when new ones post.